A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers

被引：1
|
作者：
Laura E. Pope
Kerri A. Schoedel
Cynthia Bartlett
Edward M. Sellers
机构：
[1] Avanir Pharmaceuticals,Clinical Research
[2] Inc.,undefined
[3] INC Research — Toronto,undefined
[4] DL Global Partners Inc.,undefined
来源：
Clinical Drug Investigation | 2012年 / 32卷 / 8期
关键词：
Quinidine; Memantine; Dextromethorphan; Beck Anxiety Inventory; Dextrorphan;
D O I：
10.1007/BF03261905
中图分类号：
学科分类号：
摘要：
Background and Objective: Dextromethorphan/quinidine (DMQ) is the first agent indicated for the treatment of pseudobulbar affect. Dextromethorphan, the active ingredient, is a low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. This study evaluated the potential for a drug-drug interaction (DDI) of DMQ with memantine, which is also an NMDA receptor antagonist.
引用
收藏
页码：e1 / e15
相关论文
共 50 条
  • [1] Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers
    Booker, BM
    Magee, MH
    Blum, RA
    Lates, CD
    Jusko, WJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (04) : 370 - 382
  • [2] Pharmacokinetic/pharmacodynamic modeling of dextromethorphan/quinidine for a study in pseudobulbar affect
    Brooks, Benjamin Rix
    Cummings, Jeffrey L.
    Pioro, Erik P.
    Schiffer, Randolph B.
    Wynn, Daniel R.
    Hepner, Adrian
    ANNALS OF NEUROLOGY, 2008, 64 : S38 - S38
  • [3] Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine
    Laganiere, S
    Davies, RF
    Carignan, G
    Foris, K
    Goernert, L
    Carrier, K
    Pereira, C
    McGilveray, I
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (03) : 255 - 264
  • [4] Pharmacokinetic and pharmacodynamic interactions between oseltamir and Chinese medicine formulae in healthy volunteers
    Zuo, Zhong
    Wo, Siukwan
    Tomlinson, Brian
    Fok, B.
    Ngai, Lk
    Chan, Paul K. S.
    Ngan, M. T.
    Wong, T. V.
    Chow, Moses S. S.
    DRUG METABOLISM REVIEWS, 2011, 43 : 60 - 61
  • [5] Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers
    Lee, Jieon
    Lee, Howard
    Jang, Kyungho
    Lim, Kyoung Soo
    Shin, Dongseong
    Yu, Kyung-Sang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1781 - 1788
  • [6] PHARMACOKINETIC/PHARMACODYNAMIC INTERACTIONS BETWEEN EVOGLIPTIN AND GLIMEPIRIDE IN HEALTHY MALE VOLUNTEERS.
    Yoo, H.
    Kim, Y.
    Sunwoo, J.
    Kim, Y.
    Lee, H.
    Jang, I. -J.
    Yu, K. -S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S55 - S55
  • [7] The pharmacokinetic and pharmacodynamic interactions of memantine HCL and Glucovance® in healthy young subjects
    Chou, T
    Rao, N
    Ventura, D
    Vinik, A
    Abramowitz, W
    DIABETES, 2003, 52 : A443 - A444
  • [8] Evaluation of the potential pharmacokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers
    Fleishaker, JC
    Herman, BD
    Pearson, LK
    Ionita, A
    Mucci, M
    CLINICAL DRUG INVESTIGATION, 1999, 18 (02) : 141 - 150
  • [9] Evaluation of the Potential Pharmacokinetic/Pharmacodynamic Interaction between Fluoxetine and Reboxetine in Healthy Volunteers
    Joseph C. Fleishaker
    Beth D. Herman
    Laura K. Pearson
    Antoaneta Ionita
    Massimiliano Mucci
    Clinical Drug Investigation, 1999, 18 : 141 - 150
  • [10] Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers
    Shen, Zancong
    Lee, Caroline A.
    Wallach, Kathleen
    Valdez, Shakti
    Wilson, David M.
    Kerr, Bradley
    Gillen, Michael
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (05): : 657 - 663
12345